Evommune Inc. is set to make its debut on the New York Stock Exchange on November 6, 2025, under the symbol "EVMN."
This clinical-stage biotechnology company, developing innovative therapies that target key drivers of chronic inflammatory diseases, is offering 9.38 million shares of its common stock at an initial public offering price of $16 per share. The offering is scheduled to close on November 7, 2025, and is expected to generate gross proceeds of $150 million.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com